What occurs when an permitted drug doesn’t work? Why don’t sufferers need gene remedy? And is MASH nonetheless an enormous deal?
We cowl all that and extra this week on “The Readout LOUD,” STAT’s biotech podcast. Bioethicist Holly Fernandez Lynch joins us to debate the case of Amylyx Prescription drugs’ remedy for ALS and what its failure means for drug growth. We additionally talk about the most recent information within the life sciences, together with a tepid reception for gene therapies, the way forward for CAR-T most cancers remedy, and the primary permitted medication for a prevalent liver illness.
For extra on what we cowl, right here’s extra on Amylyx; right here’s the story on hemophilia gene remedy; right here’s the information on Madrigal Prescription drugs’ drug for MASH; right here’s the place yow will discover episodes of Coloration Code; right here’s the place you possibly can subscribe to the First Opinion Podcast; and right here’s the place you possibly can subscribe to our biotech publication, The Readout.
You’ll want to enroll on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.
And when you have any suggestions for us — subjects to cowl, visitors to ask, vocal tics to stop — you possibly can e mail [email protected].
